Global longitudinal strain and plasma biomarkers for prognosis in heart failure complicated by diabetes

Nithin R. Iyer; Siew-Pang Chan; Oi Wah Liew; Jenny P.C. Chong; Jennifer A. Bryant; Thu-Thao Le; Chanchal Chandramouli; Patrick J. Cozzone; Frank Eisenhaber; Roger Foo; A. Mark Richards; Carolyn S.P. Lam; Martin Ugander; Calvin W-L. Chin

doi:10.1101/2023.03.20.23287472

Abstract

Background Heart failure (HF) and diabetes are associated with increased incidence and worse prognosis of each other. The prognostic value of global longitudinal strain (GLS) measured by cardiovascular magnetic resonance (CMR) has not been established in HF patients with diabetes.

Methods Consecutive patients (n=315) with HF underwent CMR at 3T, including GLS, late gadolinium enhancement (LGE), native T1, and extracellular volume fraction (ECV) mapping. Plasma biomarker concentrations were measured including: N-terminal pro B-type natriuretic peptide(NT-proBNP), high-sensitivity troponin T(hs-TnT), growth differentiation factor 15(GDF-15), soluble ST2(sST2) and galectin 3(Gal-3). The primary outcome was a composite of all-cause mortality or HF hospitalisation.

Results Compared to those without diabetes (n=156), the diabetes group (n=159) had a higher LGE prevalence (76 vs 60%, p<0.05), higher T1 (1285±42 vs 1269±42ms, p<0.001) and higher ECV (30.5±3.5 vs 28.8±4.1%, p<0.001). The diabetes group had higher NT-pro-BNP, hs-TnT, GDF-15, sST2 and Gal-3. Diabetes conferred worse prognosis (hazard ratio (HR) 2.33 [95% confidence interval (CI) 1.43-3.79], p<0.001). In multivariable Cox regression analysis including clinical markers and plasma biomarkers, GDF-15 and sST2 remained independently associated with the primary outcome (GDF-15: HR per 100 pg/mL 1.02 [95% CI 1.00-1.03], p=0.035; sST2: HR per 1 ng/mL 1.03 [95% CI 1.00-1.05], p=0.036). In multivariable Cox regression models in the diabetes group, GLS was prognostic (HR 1.15 [95% CI 1.06-1.25], p<0.001).

Conclusions Compared to HF patients without diabetes, those with diabetes have worse plasma and CMR markers of fibrosis and a more adverse prognosis. GLS is a powerful and independent prognostic marker in HF patients with diabetes.

Clinical Perspectives Patients with concomitant heart failure and diabetes have a particularly poor prognosis. Our study demonstrates that this group has adverse plasma and CMR markers of myocardial fibrosis. Furthermore, we have shown that GLS is a powerful and independent prognostic marker in this group. Our results raise the future possibility of GLS-guided risk stratification and management in patients with heart failure and diabetes to improve outcomes in this group.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The ATTRaCT study was supported by research grants from A*STAR Biomedical Research Council ATTRaCT program [SPF2014/003, SPF2014/004, SPF2014/005] (A*STAR, Singapore). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval was obtained from the local Centralized Institutional Review Board in Singapore, and all participants provided written informed consent. The study was conducted in accordance with the principles of the Declaration of Helsinki.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes